Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World asthma biologic use under the microscope in china

NCT ID NCT06605885

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study follows 202 Chinese asthma patients who are already prescribed biologic medications. Researchers will track how consistently patients take their biologics over 52 weeks and describe treatment patterns. No new drug is being tested; the goal is to gather real-world data on biologic use and outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

202 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 200 asthma patients will be enrolled in this study distributed among 50 sites in China.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Chinese, Female or Male 2. Age: no limitation 3. Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests). 4. Participants or their legal guardians must be able to provide informed consent. 5. Prescription of asthma biologics at enrolment. Exclusion Criteria: 6. Participation in an interventional study within the last 3 months. 7. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Research Site

    Hohhot, China, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Foshan, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Jinan, China

  • Research Site

    Kunming, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Ningbo, China

  • Research Site

    Qingdao, China

  • Research Site

    Quanzhou, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenzhen, China

  • Research Site

    Shijiazhuang, China

  • Research Site

    Suining, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Ürümqi, China

  • Research Site

    Wenzhou, China

  • Research Site

    Wuhan, China

  • Research Site

    Wuxi, China

  • Research Site

    Xi'an, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Zhuhai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.